India Ends Over-the-Counter Sales of Cough Syrups
New rules notified June 9 strip syrups of a decades-old exemption, so cough mixtures can no longer be bought without a prescription after children died from tainted batches.
India has ended the freewheeling sale of cough syrups. Under new rules now in force, no syrup medicine, cough mixtures included, can be sold without a doctor’s prescription, closing a long-standing loophole that let them move across pharmacy counters like sweets.
The change comes through the Drugs (Fifth Amendment) Rules, 2026, notified in the Gazette of India on June 9. It strikes the word “syrups” from an exemption in the country’s 1945 drug rules that had allowed them to be sold without the stricter controls applied to most prescription medicines. In practical terms, a chemist can no longer hand over a bottle of cough syrup on request.
The trigger was tragedy. Over the past year, contaminated cough syrups were linked to the deaths of children in the states of Madhya Pradesh and Rajasthan, part of a wider reckoning over the safety of India’s vast pharmaceutical industry, which supplies much of the world’s generic medicine. Indian-made syrups have also been tied to child deaths abroad in recent years, drawing World Health Organization warnings.
The prescription rule addresses one risk, unsupervised use, but not the other: contamination at the point of manufacture. Toxic syrups have typically been poisoned when industrial solvents are substituted for pharmaceutical-grade ingredients, a quality-control failure a prescription requirement does not by itself fix. Officials have framed the measure as one layer among several, alongside tighter testing and oversight of manufacturers.
The stakes are global as much as domestic. India is often called the “pharmacy of the world,” supplying a large share of the generic medicines used across Africa, Asia and beyond. In 2022 and 2023, cough syrups made in India were linked to the deaths of dozens of children in Gambia and Uzbekistan from diethylene glycol poisoning, prompting World Health Organization alerts and tighter export testing. The new domestic rule extends that scrutiny to the home market.
For Indian parents, the immediate effect is friction: a sick child at midnight now means a prescription, not a quick stop at the pharmacy. Public-health officials are betting the inconvenience is worth it, that fewer casual purchases and more medical oversight will, over time, mean fewer children harmed by medicines meant to help them.
